SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51: 1536.
  • 2
    Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin N Am 1996;23: 633650.
  • 3
    Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal 125I implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14: 449453.
  • 4
    Stone NN, Stock RG. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. Tech Urol 1995;1: 7280.
  • 5
    Beyer DC, Priestley JB Jr. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys 1997;37: 559563.
  • 6
    Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ Jr. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 2000;164: 738741.
  • 7
    Vicini FA, Kestin LL, Stromberg JS, Martinez AA. Brachytherapy boost techniques for locally advanced prostate cancer. Oncology (Huntington) 1999;13: 491499.
  • 8
    Critz FA, Tarlton RS, Holladay DA. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. 125I implant followed by external-beam radiation. Cancer 1995;75: 23832391.
  • 9
    Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak DC, Cavanagh W. 103Pd brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46: 839850.
  • 10
    Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32: 465471.
  • 11
    Desai J, Stock R, Stone N, Iannuzzi C, DeWyngaert JK. Acute urinary morbidity following 125I interstitial implantation of the prostate gland. Radiat Oncol Invest 1998;6: 135141.
  • 12
    Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implants: iodine125 vs. palladium103. Radiat Oncol Invest 1998;6: 135141.
  • 13
    Ling CC. Permanent implants using Au-198, 103Pd and 125I: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23: 8187.
  • 14
    Dicker AP, Lin CC, Leeper DB, Waterman FM. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry. Sem Urol Oncol 2000;18: 152159.
  • 15
    Orton CG. Time-dose factors (TDFs) in brachytherapy. Br J Radiol 1974;47: 603.
  • 16
    Waterman FM. Yue N. Corn BW. Dicker AP. Edema associated with 125I and 103Pd prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998;41: 10691077.
  • 17
    Waterman FM. Dicker AP. The impact of postimplant edema on the urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47: 661664.
  • 18
    Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Correlation of the American Urologic Association Symptoms index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptoms indexes. Measurement Committee of the American Urological Association. J Urol 1992; 148: 15581563.
  • 19
    Molenberghs G, Verbeke G. Linear mixed models in practice: an SAS-oriented approach. New York: Springer-Verlag; 1997.
  • 20
    Ling CC, Li WX, Anderson LL. The relative biologic effectiveness of 125I and 103Pd. Int J Radiat Oncol Biol Phys 1995;32: 373378.
  • 21
    Brown D, Colonias A, Miller R, Cohen J, Arshoun Y, Galloway M, Karlovitz S, Wu, A, Johnson M, Quinn A, Kalnicki S. Urinary morbidity with a modified peripheral loading technique of transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 2000;47: 353360.
  • 22
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Donzella JG. Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology 2001;57: 524529.
  • 23
    Gelblum DY, Potters L, Ashley R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45: 5967.
  • 24
    Dattoli M, Wallner K, Sorace R, Koval J, Cash J, Acosta R, Brown C, Etheridge J, Binder M, Brunelle R, Kirwan N, Sanchez S, Stein D, Wasserman S. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35: 875879.
  • 25
    Joly F, Brune D, Couette JE, Lesaunier F, Heron JF, Peny J, Henry-Amar M. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998;9: 751757.
  • 26
    Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998;160: 9195.
  • 27
    Ragde H, Elgand AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, Korb LJ. Ten year disease free survival after transperineal sonography-guided I-125 brachytherapy with or without 45 Gy external beam irradiation in treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83: 9891001.
  • 28
    Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001;219: 817821.